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ABSTRACT 
 
We synthesized a series of polyoxometalate-bisphosphonate complexes containing Mo
VI
O6 
octahedra, zoledronate or an N-alkyl (n-C6 or n-C8) zoledronate analog, and in two cases, Mn 
as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were  
 2 
characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental 
and EDX analysis and  
31
P NMR. We found promising activity against human non-small cell 
lung cancer (NCI-H460) cells with IC50 values for growth inhibition of ~5 M per 
bisphosphonate ligand. The effects of bisphosphonate complexation on IC50 decreased with 
increasing bisphosphonate chain length: C0 ~6.1x; C6 ~3.4x and C8 ~1.1x. We then 
determined the activity of one of the most potent compounds in the series, Mo4Zol2Mn(III), 
against SK-ES-1 sarcoma cells in a mouse xenograft system finding a ~5x decrease in tumor 
volume than found with the parent compound zoledronate at the same compound dosing (5 
g/mouse). Overall, the results are of interest since we show for the first time that 
heteropolyoxomolybdate-bisphosphonate hybrids kill tumor cells in vitro and significantly 
decrease tumor growth, in vivo, opening up new possibilities for targeting both Ras as well as 
EGFR (epidermal growth factor receptor)  driven cancers. 
 
INTRODUCTION 
Polyoxometalates (POMs) constitute a class of discrete, anionic, metal-oxygen clusters which 
can be considered as soluble oxide fragments. They are built from the connection of {MOx} 
polyhedra, M being a d-block transition metal ion in a high oxidation state, usually W
VI
, 
Mo
V,VI
 or V
IV,V
.
1
 They can incorporate a large range of organic or inorganic species into their 
structures. This results in a great variety of sizes, nuclearities and shapes
2
 and a vast range of 
photochemical
3
, catalytic
4 , 5
 , magnetic
6 , 7
  as well as biological properties including  
antibacterial,
8
 antiviral and antitumoral activities.
9
 POMs can also have activity in tumor cell 
growth inhibition, e.g.  [NH3Pr
i
]6[Mo7O24].3H2O exhibits potent anti-tumor activity against 
breast, sarcoma, adenocarcinoma and pancreatic cancer cells.
10
 The anti-tumor activities in 
vitro of a variety of polyoxotungstates have also been reported and organometallic derivatives 
with RSn
11
 or CpTi
12
 (Cp = cyclopentadienyl) groups appear to be the most efficient. 
 3 
Recently, the cobalt derivative {CoSb6O4(H2O)3[Co(hmta)SbW8O31]3}
15-
 (hmta = 
hexamethylenetetramine) was also shown to kill various cancer cells.
13
 Polyoxometalates, in 
particular Dawson-type [P2Mo18O62]
6- 
anions, were also identified as inhibitors of protein 
kinase CK2, a multifunctional kinase that is deregulated in many cancers.
14
  
In order to try and improve activity, one approach is to graft bioactive organic ligands 
on the inorganic POM core. However, examples of this approach are rare. Organoimido- 
derivatives of hexamolybdate based on amantadine, an antiviral and anti-Parkinson drug, have 
been tested in vitro against MCF-7 cells and exhibit better activity than do unfunctionalized 
hexamolybdate and amantadine.
15
 Cholic acid was also grafted onto the tris-modified 
Anderson-type POM [MnMo6O18{(OCH2)3CNH2}2]
3-
, resulting in enhanced activity over the 
non-functionalized POM against breast cancer cells (MCF-7, IC50~56 M and MDA-MB-
231, IC50~38 M).
16
 A variant of this approach consists of grafting a cleavable group onto a 
hexamolybdate POM in order to improve degradability with one such hybrid POM being 
reported to exhibit good activity against human malignant glioma cells (U251, IC50~25 M), 
the ability to penetrate the blood brain barrier, as well as low toxicity towards rat 
pheochromocytoma cells (PC12).
17
  
In our group, we have been investigating polyoxometalate-bisphosphonate complexes. 
Bisphosphonates (BPs) having the general formula H2O3PC(OH)(R)PO3H2 have been used 
clinically for decades to treat bone resorption diseases and some of them exhibit anti-tumor 
activity.
18
 Once deprotonated, BPs can form complexes with Mo, W or V ions, with 
nuclearities ranging from 1 to 12.
19
 In our first investigation, we reported the anti-cancer 
activity of hybrid POM/alendronate (Ale) complexes.
20
 The dodecanuclear complex 
[(Mo
VI
3O8)4(Ale)4]
8-
,  noted here Mo12Ale4, had IC50 values of ~10 µM against  human breast 
cancer cells (MCF-7) in vitro. This value represents about 4x the activity of the parent 
alendronate molecule (i.e. on a per-alendronate basis), indicating a potentiating or synergistic 
 4 
effect. We then extended our study to include zoledronate (Zol; Figure 1), the most potent 
commercially available bisphosphonate, and synthesized the hexanuclear complex 
[(Mo
VI
3O8)2O(Zol)2]
6-
.
21
 We also investigated the incorporation of a heterometal finding that 
the most active compound was the Mn(III)-containing POM [(Mo
VI
2O6)2(Zol)2Mn]
5-
, a.k.a. 
Mo4Zol2Mn(III), suggesting a possible role for both the heterometal and the BP in growth 
inhibition.
22
   
Here, we describe the synthesis and characterization of a new series of POM/BP 
complexes and investigate the influence of the oxidation state of the Mn, and the introduction 
of alkyl chains grafted onto the zoledronate core, on the in vitro activity of these compounds 
against human non-small cell lung cancer (NCI-H460) cells. Lipophilic chains were expected 
to improve cell uptake of the hybrid POMs since it is known that lipophilic BPs have 
activities far greater than do non-lipophilic BPs in inhibiting tumor cell growth and 
invasiveness, both in vitro and in vivo.
23
 Furthermore, a recent study revealed that lipophilic 
zoledronates inhibit both farnesyl and geranylgeranyldiphosphate synthases, effectively 
blocking prenylation of KRAS and other small G-proteins critical for tumor growth and cell 
survival.
24
 Finally, we report the first results of in vivo xenograft tumor experiment with a 
POM/BP/Mn complex.  
 
RESULTS AND DISCUSSION 
In order to test the effect of the introduction of a lipophilic chain onto the BP-ligand on tumor 
cell growth inhibition, two zoledronate-based bisphosphonates, ZolC6 and ZolC8 (Figure 1), 
were selected for synthesis of Mo/BP complexes. ZolC6 and ZolC8 are zoledronate analogs 
that have N-alkyl chains (n-C6 or n-C8) on the unsubstituted nitrogen in the parent 
zoledronate. These ligands were chosen because they were previously found to be the most 
active (of Zol analogs containing between 0 and 15 carbon substituents) against a range of 
 5 
tumor cell lines.
24
 Two families of complexes were investigated: Mo6L2 (L = Zol, ZolC6, 
ZolC8), or with Mn(III) as the heterometal and with general formulae Mo4L2Mn(III) (L = Zol, 
ZolC8). The structures and ligand abbreviations as well as the structures of all of the 
complexes reported in this study are shown in Figure 1.  
 
 
 
 
 
 
 
 
 
Figure 1. Abbreviations and formulae of the BPs used in this study together with schematic 
structures of some complexes. Grey polyhedra = MoO6, purple polyhedron = MnO6, green 
spheres = P, black spheres = C, red spheres = O. 
 
 
Synthesis and Characterization.  
Mo6Zol2 was synthesized as a reference according to a previously reported procedure.
21
 
Mo(VI) complexes with lipophilic bisphosphonates were synthesized by reaction of the BP 
precursor with Mo(VI) ions in aqueous solution at pH ~5. While it was possible to isolate 
single crystals suitable for X-ray diffraction by slow evaporation of the reaction mixture for 
Mo6(ZolC6)2, only a poorly crystalline powder could be obtained for the Mo6(ZolC8)2 
complex. However, the similarity of the IR spectra (Figure S1a) and of the 
31
P NMR spectra 
(Figure S2) of both compounds, as well as the results of elemental analysis, confirm 
formation of Mo6(ZolC8)2. Mo4Zol2Mn(III) was synthesized following a slight modification 
Zol ZolC6
N
N
PO3H2
PO3H2
OH N+
N
PO3H2
PO3H2
OH N
+ N
PO3H2
PO3H2
OH
ZolC8
Mo4L2Mn(III) (L = Zol, ZolC8)
Mo4L2Mn(II) (L = Zol)
Mo6L2 (L = Zol, ZolC6, ZolC8)
R
R
L = 
R PO3H2
PO3H2
OH
R
R
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of the procedure reported previously.
22
 Mo4Zol2Mn(II) was synthesized by reduction of 
Mo4Zol2Mn(III). Attempts to reduce this complex in solution failed so its reduction was 
performed by adding ascorbic acid to a suspension of crystals in methanol, as described for a 
Mn(III)-containing polyoxotungstate.
25
 A color change of the crystals from gray to yellow 
was observed. This implies that the Mo(VI) centers have not been reduced, because if they 
were, a blue coloration would be expected. The MT vs. T curve for this compound is shown 
in Figure S3 where it can be seen that the MT product is nearly constant between 300 to 50 K 
(MT = 4.15 cm
3
mol
-1
K at 300 K), with a decrease at low temperature (MT = 2.68 cm
3
mol
-1
K 
at 2K) which can be attributed to the zero-field splitting effect. This indicates that 
Mo4Zol2Mn(III) has been fully reduced to Mo4Zol2Mn(II) (at room temperature, the 
calculated MT values are 2.94 cm
3
mol
-1
K for a Mn(III) monomer and 4.29 cm
3
mol
-1
K for a 
Mn(II) monomer assuming g = 1.98). As expected, the IR spectra of the oxidized and reduced 
POMs are very similar (Figure S1b). The synthesis of Mo4(ZolC8)2Mn(III) was performed by 
reacting Mn(OAc)3 and ZolC8 with a large excess of Na2MoO4 in acetate buffer. The reaction 
with a stoichiometric amount of Mo(VI) ions gave only an insoluble unidentified powder. 
Mo4(ZolC8)2Mn(III) was characterized by IR spectroscopy (Figure S1c), elemental analysis 
and EDX (energy dispersive X-ray analysis) measurements. Despite many attempts, we were 
unable to isolate the analogous compound with the ZolC6 bisphosphonate. 
     31
P NMR spectroscopy was used to determine whether structures characterized in the solid 
state were maintained in solution. The 
31
P NMR spectrum of Mo6(ZolC6)2 dissolved in water 
at room temperature exhibits two singlets at 17.12 and 16.82 ppm with relative intensities 
0.63:1.37 (Figures 2 and S2a). The same behavior is observed for Mo6(ZolC8)2 with two 
singlets at 17.46 and 16.82 ppm with relative intensities 0.89:1.1 (Figure S2b). Only one 
singlet was expected if the structure observed in the solid state (Figure 3) was retained in 
solution, corresponding to four equivalent phosphorus nuclei. However the presence of 
 7 
another singlet close to the first one has already been observed for other hexanuclear 
complexes
21
 and has been attributed to an equilibrium between two conformers which differ 
by the rotation of the two {Mo3O8} groups around the central oxo bridge (Figure S4). The two 
resonances are relatively sharp at room temperature and broaden when the temperature 
increases and finally coalesce at 70°C (Figure 2), indicating that, as expected, dynamic 
exchange between the two conformers increases on heating.  
 
 
 
 
 
Figure 2. 
31
P{
1
H} NMR spectra of Mo6(ZolC6)2 dissolved in D2O at two different 
temperatures. 
 
We also studied the stability of Mo6(ZolC6)2 and Mo6(ZolC8)2 under more physiological 
conditions (0.1 M KH2PO4 buffer, pH = 7.4, 0.12 M NaCl, 37°C) (Figure S2). The 
31
P NMR 
spectrum of Mo6(ZolC6)2 exhibits two peaks, as observed for the aqueous solution, 
confirming the stability of the complex. In the spectrum of Mo6(ZolC8)2, one of the peaks is 
split, which may be attributable to the existence of several conformers which could result 
from different positions of the alkyl chains, as seen in the crystal structure of Mo6(ZolC6)2 
(vide infra). It can also be seen that the 
1
H NMR spectra of Mo6(ZolC8)2 in water and in the 
more physiological conditions are identical (Figure S5). 
d / ppm
111213141516171819202122232425
70 C
Room temperature
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Structures.  
The structure of Mo6(ZolC6)2 was determined by means of single-crystal X-ray diffraction. 
There are two crystallographically independent molecules (Figure 3) and the structure of the 
inorganic core is identical in both molecules. Two {Mo3O8} trimeric units are connected by a 
central oxygen atom and in each trimer, Mo(VI) ions are connected to a pentadentate BP 
ligand by P-O-Mo and C-O-Mo bonds. The six Mo(VI) ions are coplanar, as usually observed 
for hexanuclear Mo(VI) complexes with BP ligands.
19b
 The differences between both 
complexes lie in the position of the C6 alkyl chain on the imidazole ring. In one of the 
molecules (Molecule A, Figure 3a) the chain is bent and there are short C-H
…
O distances (dC-
H…O in the 2.33-2.80 Å range).
26
 In the other molecule (Molecule B, Figure 3b) the alkyl 
chain is extended away from the cluster. Molecules A and B stack into columns that align in 
the unit-cell (Figure 3c). 
 
 
 
 
 
 
 
 
 
 
Figure 3. Representation of the two crystallographically independent molecules a) A and b) B 
in the structure of Mo6(ZolC6)2. c) View of the crystal packing. Purple octahedra = MoO6 
octahedra in molecule A, grey octahedra = MoO6 octahedra in molecule B, green spheres = P, 
black spheres = C, small black spheres = H, blue spheres = N, red spheres = O, hydrogen 
bonds are represented as dotted lines. 
 
a) b)
c)
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In the Mo4L2Mn complexes, IR, elemental analysis and EDX measurements indicate that the 
Mo4L2Mn(III) (L = Zol, ZolC8) and Mo4Zol2Mn(II) complexes have structures that are similar 
to Mo4Zol2Fe.
22
 That is, two {Mo2O6} dimeric units with faced-shared Mo(VI) octahedra are 
bound to an octahedrally coordinated central Mn ion (Figure 1) and two BP ligands are 
connected to the Mo and Mn ions through P-O-M and C-O-M (M = Mo, Mn) bonds.  
In vitro and in vivo results.  
We next investigated the effects of the new compounds (together with some compounds 
reported previously) on tumor cell growth inhibition using the non-small cell human lung 
cancer cell line NCI-H460. Representative dose-response curves are shown in Figure 4 for 
zoledronate (Figure 4a), Mo4Zol2Mn(II) (Figure 4b), Mo6(ZolC6)2 (Figure 4c) and 
Mo4(ZolC8)2Mn(III) (Figure 4d).  
 
 
 
 
 
 
 
 
 
Figure 4. Dose response curves for NCI-H460 cell growth inhibition. a) zoledronate. b)  
Mo4Zol2Mn(II). c) Mo6(ZolC6)2. d) Mo4(ZolC8)2Mn(III). Three replicates of duplicates were 
determined, representative data from one duplicate set are shown. 
 
IC50 values for all compounds are reported in Table 1 on both a molecular weight as well as 
on a per-bisphosphonate basis. We anticipated that there would be a large increase in activity 
of the POM/BP complexes containing the more lipophilic bisphosphonates since the 
 10 
lipophilic bisphosphonates acting alone are more active than is zoledronate. With the 
zoledronate complexes we find that the new Mo4Zol2Mn(II) complex has potent activity (on a 
per bisphosphonate basis), Figure 4b, similar to that of Mo4Zol2Mn(III), on average ~6x the 
activity of zoledronate acting alone and considerably more activity than the Mo6Zol2 complex, 
Table 1. This suggests that the oxidation state of Mn has little influence on the activity of the 
complex. It can also be seen that zoledronate and the Mo4Zol2Mn(III) complex are about 2x 
more potent in MCF-7 than in NCI-H460 cell lines, as reported previously,
22
 reflecting not 
unexpected cell-to-cell variability. With the ZolC6 system we obtained more activity with the 
Mo6(ZolC6)2 system than with ZolC6 alone. However, with the more lipophilic ZolC8 species, 
the activities of all three species: ZolC8, Mo6(ZolC8)2 and Mo4(ZolC8)2Mn(III) (Figure 4d) are 
quite similar to each other as well as to the Mo4Zol2Mn complexes, Table 1.  
 
Table 1. Growth inhibition of human cancer cell line NCI-H460 by bisphosphonates and 
POM/BP complexes 
 
Formula IC50 [µM] IC50 [µM] per BP 
IC50 decrease 
vs BP 
Mo6Zol2 10±0.9 20±1.8 1.4x 
Mo4Zol2Mn(III) 2.6±0.3 5.2±0.6 5.4x 
Mo4Zol2Mn(II) 2.0±0.1 4.0±0.2 7.0x 
Zol 28±3 28±3 1.0x 
Mo6(ZolC6)2 3.5±0.1 7.0±0.2 3.4x 
ZolC6 24±0.8 24±0.8 1.0x 
Mo6(ZolC8)2 1.9±0.2 3.8±0.4 1.3x 
Mo4(ZolC8)2Mn(III) 2.9±0.3 5.8±0.6 0.9x 
ZolC8 5.1±0.2 5.1±0.2 1.0x 
      
We thus next moved to in vivo studies which since the pioneering work of Yamase and 
coworkers
10a
 have been quite rare.
27
 Since there were only small differences in IC50 values on 
a per-bisphosphonate basis between the most active species, we chose to investigate the 
Mo4Zol2Mn(III) species reported earlier in our in vivo study, for the following reasons: i) it 
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has good activity in both the H460 (lung cancer) cell line described here, as well as against 
the MCF-7 (breast cancer) cell line reported previously;
22
 ii) zoledronate is commercially 
available while the alkyl zoledronates require several additional synthesis steps; iii) 
zoledronate is already used clinically while the alkyl zoledronates are not; iv) synthesis of the 
Mo4Zol2Mn(II) complex requires formation of the Mn(III) complex followed by the reduction 
of the Mn(III) crystals by ascorbate-again an additional synthetic step and v) there is little 
difference in activity between the Mn(II) and Mn(III) complexes, due perhaps to reduction of 
the latter in cells.   
     We used the mouse xenograft (SK-ES-1 sarcoma tumor cell growth) model because in 
previous work we used this system to investigate the effects of lipophilic bisphosphonate 
chain-length variation on tumor cell growth where we found that a very lipophilic pyridinium 
analog of zoledronate (BPH-715, containing an n-C10 alkyloxy side-chain) resulted in a ~5x 
decrease in tumor volume versus zoledronate.
23
 Representative results for PBS control, 
zoledronate and Mo4Zol2Mn(III)  treated mice as a function of time are shown in Figures S6a-
c and tumor cell volumes as a function of time are shown in Figure 5a. As can be seen in 
Figure 5a, there is a very significant (p = 0.045) decrease in tumor cell volume with 
Mo4Zol2Mn(III) dosed at 5 g/mouse via intra-tumoral injection once a day for 28 days, 
corresponding to a ~5x decrease in tumor cell growth versus zoledronate, even though there 
was only ~1/3 the amount of zoledronate present in the Mo4Zol2Mn(III) treatment (due to the 
high mass of the POM cluster). There was also only a small difference in mice body weight 
on zoledronate or Mo4Zol2Mn(III) treatment, Figure 5b, showing the absence of any increased 
toxicity of the complex versus zoledronate alone therapy. These relatively low 
bisphosphonate concentrations (compared with zoledronate or BPH-715 levels) may make 
such hybrids in general less toxic than bisphosphonates acting alone, although further work 
will be needed to investigate this possibility. In the future, it may be possible to carry out 
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detailed structure-activity relationships investigations of these types of complex, although this 
will be very challenging since it will be necessary to know cell concentrations of the 
complexes, their stability, as well as the targets for the Mo-moiety as well as the Mn. Plus, as 
briefly discussed below, both protein prenylation as well as kinase inhibition can be targeted 
by bisphosphonates.  
  
  
 
 
 
 
 
 
Figure 5. a) Effects of zoledronate and Mo4Zol2Mn(III) on SK-ES-1 tumor volume as a 
function of time (weeks 1, 2, 3 and 4) in 6-week old athymic nude mice treated daily for 28 
days with 5 g compound or phosphate-buffered saline (PBS); 6 mice per group. b) Body 
weights as a function of time for different treatments. 
 
Conclusions 
We synthesized and characterized four new POM/BP complexes: Mo6L2 (L=ZolC6, ZolC8), 
Mo4(ZolC8)2Mn(III) and Mo4Zol2Mn(II), and tested them, together with previously reported 
analogs, in vitro against a human non-small cell lung cancer cell line NCI-H460. The most 
active compounds had IC50 values of ~ 4-5 M (on a per-bisphosphonate basis), about 6x 
more active than zoledronate itself (IC50 = 28 M). One of the most active compounds tested 
here in vitro was also the most active compound against the MCF-7 breast cancer cell line 
reported previously, so was investigated in vivo against SK-ES-1 sarcoma cells in a mouse 
xenograft system. There was a five-fold decrease in tumor cell volume versus that found with 
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zoledronate after a 28 day treatment period at 5 g/mouse dosing (~0.2 mg/kg). At present, 
the molecular basis for the enhanced activity (over that seen with bisphosphonates alone) 
remains to be determined since both masking of bisphosphonate charge, increasing cell 
permeability, as well as potentiation of bisphosphonate activity by the (hetero)polymolybdate 
moiety may be involved.  Nevertheless, the results are of considerable interest because they 
show for the first time that POM/BP/Mn complexes have potent in vivo activity.  
     What is particularly attractive about the use of bisphosphonates as ligands in POM 
complexes is that zoledronate, for example, has the potential for targeting both Ras as well as 
EGF (epidermal growth factor)-driven tumors. Zoledronate inhibits farnesyl diphosphate 
synthase and this leads to inhibition of Ras prenylation. Moreover, in two recent articles
28
 
zoledronate has also been shown to lead to inhibition of EGFR signaling/phosphorylation. It 
may thus be possible to develop POM-bisphosphonate compounds that target both EGFR as 
well as Ras-driven cancers. Zoledronate is also an important POM-ligand since zoledronate 
itself activates gamma-delta T cells (containing the V2Vd2 T cell receptor) to kill tumor 
cells,
29
 it switches macrophages from an M2 (tumor promoting) to an M1 (tumor killing) 
phenotype
30
 and inhibits angiogenesis/invasiveness. There are thus good reasons to believe 
that POM/bisposphonate/Mn complexes may find utility as drug leads for combination 
therapies against both Ras as well as EGFR-driven cancers, that also target innate immunity. 
 
EXPERIMENTAL SECTION 
Experimental Procedures and Characterization. Zoledronic acid 
H2O3PC(C4H5N2)(OH)PO3H2 (H5Zol)
31
 and (NH4)6[(Mo3O8)2O(O3PC(C4H6N2)OPO3)2]∙9H2O 
(Mo6Zol2)
21
 were synthesized according to reported procedures. Li2H2(ZolC6) and 
Li2H2(ZolC8) were synthesized with a protocol adapted from  literature procedures
24
 (see 
Supplementary Information).    
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Synthesis of (NH4)6[(Mo3O8)2O(O3PC(C4H5N2)(C6H13)(O)PO3)2]8H2O (Mo6(ZolC6)2): 
(NH4)6Mo7O24.4H2O (0.120 g, 0.10 mmol) was dissolved in 5 mL of 1M NH4OAc/HOAc 
buffer before addition of Li2H2(ZolC6) (0.106 g, 0.24 mmol). The mixture was sealed in a 23-
mL Teflon-lined stainless steel reactor before heating to 130°C over a period of 1 h, kept at 
this temperature for 20 h, then cooled to room temperature over a period of 36 h. The 
resulting colorless crystals were collected by filtration. Yield: 0.144 g (68% based on Mo). 
31
P 
NMR (300 MHz, D2O, 25°C): δ 17.12 (s), 16.76 (s). 
1
H NMR (300 MHz, D2O, 60°C, water 
saturation): 9.07 (d, 1H, NCHCHN), 7.83 (d, 1H, NCHCHN), 7.63 (s, 1H, NCHN), 5.07 and 
4.94 (2m, 2H, NCH2C), 4.44 (t, 2H, NCH2CH2), 2.14 (m, 2H, NCH2CH2CH2), 1.59 (m, 6H, 
CH2), 1.14 (m, 3H, CH3). IR (FTR): ν (cm
-1
) = 1640 (w), 1566 (w), 1433 (vs), 1152 (s), 1127 
(s), 1086 (s), 1062 (sh), 1048 (s), 978 (m), 928 (sh), 912 (s), 875 (vs), 730 (vs), 698 (s), 629 
(s), 560 (m), 518 (m), 482 (m). Anal. Calc. (found) for C22H76N10Mo6O39P4 (1804.4 g mol
-1
): 
C 14.64 (14.40), H 4.25 (3.99), N 7.76 (7.69). EDX measurements confirm the Mo/P ratio. 
Synthesis of (NH4)6[(Mo3O8)2O(O3PC(C4H5N2)(C8H17)(O)PO3)2]10H2O (Mo6(ZolC8)2): 
Na2MoO4.2H2O (0.096 g, 0.40 mmol) was dissolved in 1.5 mL of water (sol. A); 
Li2H2(ZolC8) (0.055 g, 0.12 mmol) was dissolved in 1.5 mL of water acidified with 2 drops of 
1M hydrochloric acid (sol. B). Sol B was added to sol. A and 1M HCl was added dropwise to 
pH = 5. NH4Cl (0.600 g, 11.3 mmol) was added, resulting in the precipitation of a fine white 
powder. The mixture was allowed to stir at room temperature for 20 min. The powder was 
filtered and dried with ethanol and diethyl ether. Yield: 0.061 g (48% based on Mo). 
31
P NMR 
(300 MHz, D2O, 25°C): δ 17.46 (s), 16.82 (s). 
1
H NMR (300 MHz, D2O, 60°C, water 
saturation): 9.08 (d, 1H, NCHCHN), 7.86 (d, 1H, NCHCHN), 7.65 (s, 1H, NCHN), 5.05 and 
4.96 (m, 2H, NCH2C), 4.46 (t, 2H, NCH2CH2), 2.17 (m, 2H, NCH2CH2CH2), 1.61 and 1.56 
(m, 10H, CH2), 1.13 (m, 3H, CH3). IR (FTR): ν (cm
-1
) = 1560 (w), 1414 (vs), 1153 (sh), 1134 
(s), 1083 (m), 1058 (sh), 1048 (s), 980 (m), 917 (s), 876 (vs), 792 (w), 732 (m), 690 (s), 619 
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(s), 578 (m), 556 (m), 533 (m), 487 (w), 458 (w). Anal. Calc. (found) for C26H88N10Mo6O41P4 
(1896.5 g mol
-1
): C 16.47 (16.69), H 4.68 (4.51), N 7.39 (7.36). EDX measurements confirm 
the Mo/P ratio. 
Synthesis of (NH4)5[(Mo
VI
2O6)2(O3PC(C4H6N2)OPO3)2Mn
III
].10H2O (Mo4Zol2Mn(III)): 
To a solution of Na2MoO4·2H2O (0.242 g, 1 mmol) in 10 mL of 1M 
CH3COONH4/CH3COOH buffer was added Mn(OAc)3·2H2O (0.070 g, 0.26 mmol) and 
zoledronic acid (0.137 g, 0.5 mmol). The solution was stirred for 5 min then NH3 (33% in 
water) was added dropwise to pH = 7.5. The solution was left to evaporate and was filtered 
after 24 h in order to remove a pink precipitate. EDX measurements and IR spectroscopy 
indicated that the precipitate was a BP complex that did not contain molybdenum. An 
homogeneous gray crystalline phase of the title compound appeared after three days (see 
picture in Figure S7). Yield: 0.080 g (21% based on Mo). Anal. Calc. (found) for 
C10H52MnMo4N9O36P4 (1437.2 g mol
-1
): C 8.36 (8.88), H 3.65 (3.90), N 8.77 (8.78). IR 
(FTR): ν (cm-1) = 1575(m), 1546 (w), 1421(s), 1288 (w), 1136(s), 1112(sh), 1045(s), 
1018(sh), 973(m), 915(s), 888(s), 790(s), 699(m), 656(m), 619(w), 560(w), 529(m). EDX 
measurements confirm the Mo/P and Mo/Mn ratios. 
Synthesis of (NH4)5(H3O)[(Mo
VI
2O6)2(O3PC(C4H6N2)OPO3)2Mn
II
].6H2O.4CH3OH 
(Mo4Zol2Mn(II)): Ascorbic acid (0.150 g, 0.85 mmol) was added to a suspension of 
Mo4Zol2Mn(III) (0.190 g, 0.13 mmol) in 30 mL of MeOH. The solution was stirred for 6 h 
and was filtered. The resulting pale yellow solid was washed with MeOH and dried. Yield: 
0.129 g (68%). IR (FTIR) : ν (cm-1) = 1579(m), 1546 (w), 1418(s), 1286 (w), 1137(s), 
1112(sh), 1047(s), 1018(sh), 975(m), 911(s), 887(s), 786(s), 699(m), 659(m), 619(w), 561(w), 
529(m), 485(w). Anal. Calc. (found) for C14H63N9MnMo4O37P4 (1512.3 g mol
-1
): C 11.12 
(11.02), H 4.20 (3.47), N 8.34 (7.98). EDX measurements confirm the Mo/P and Mo/Mn 
ratios. 
 16 
Synthesis of Li2(NH4)3[(Mo
VI
2O6)2(O3PC(C4H5N2)(C8H17)OPO3)2Mn
III
].8H2O 
(Mo4(ZolC8)2Mn(III)): Na2MoO4.2H2O (0.197 g, 0.82 mmol) was dissolved in 5 mL of 1M 
NH4OAc/HOAc and Mn(OAc)3.2H2O (0.018 g, 0.048 mmol) was added. A solution of 
Li2H2(ZolC8) (0.027 g, 0.060 mmol) in 3 mL of H2O acidified with a few drops of 1M HCl 
until dissolution was slowly added. The pH was adjusted to 5.8 with 33% NH3. The solution 
was stirred for 2 hours and an orange crystalline precipitate which did not contain ZolC8 was 
removed by filtration. The pH of the solution was equal to 6.1. The solution was left at room 
temperature for 5 days and the thin pinkish platelets (see picture in Figure S7) of the title 
compound were removed by filtration. Yield 0.011 g (23% based on ZolC8). IR (FTIR) : ν 
(cm
-1
) = 1639(w), 1661(m), 1420(s), 1123(m), 1046(s), 990(w), 912(m), 871(s), 796(w), 
743(w), 691(m), 620(m), 661(m). Anal. Calc. (found) for C26H64Li2N7MnMo4O36P4 (1627.3 g 
mol
-1
): C 19.19 (19.97), H 3.96 (4.18), N 6.03 (5.80). EDX measurements confirm the Mo/P 
and Mo/Mn ratios. 
Infrared spectra were recorded on a Nicolet 30 ATR 6700 FTIR spectrometer. 
Crystal Structure Determination. Single crystal X-ray diffraction data for Mo6(ZolC6)2 
were collected by using a Bruker Nonius X8 APEX 2 instrument equipped with a CCD 
bidimensional detector using the monochromatised wavelength (Mo K) = 0.71073 Å. 
Absorption corrections were based on multiple and symmetry-equivalent reflections in the 
data set using the SADABS program
32
 based on the method of Blessing.
33
 The structure was 
solved by direct methods and refined by full-matrix least-squares using the SHELX-TL 
package.
34
 NH4
+
 and H2O could not be distinguished based on the observed electron densities, 
therefore, all positions were labelled as O and assigned the oxygen atomic diffusion factor. 
Crystallographic data are given below and the complete data can be found in the cif file 
CCDC 1547689.  
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Crystal data for compound Mo6(ZolC6)2: C22H36Mo6N4O41P4, M = 1712.07 g mol
-1
, Triclinic, 
space group P-1, a = 8.8527(6) Å, b = 16.8404(11) Å, c = 19.6929(13) Å,  = 81.370(2)°,  = 
83.028(2)°,  = 76.955(2)°, V = 2816.0(3) Å3, T = 296 K, Z = 2, Dc = 2.019 g cm
-3
,  = 1.515 
mm
-1
, GooF = 1.145, Final R indices (I ≥ 2(I)) R1 = 0.0406, wR2 = 0.1191. 
Powder X-ray. Powder X-ray diffraction data were obtained on a Bruker D5000 
diffractometer using Cu radiation (1.54059 Å). The comparison of the experimental X-ray 
powder pattern with the powder pattern calculated from the structure solved from single-
crystal X-ray diffraction data confirm the homogeneity of Mo6(ZolC6)2 (Figure S8). 
EDX Measurements. EDX measurements were performed on a JEOL JSM 5800LV 
instrument.  
NMR measurements. 31P NMR spectra were recorded in 5 mm tubes with 1H decoupling by 
using a Bruker AC-300 spectrometer operating at 121.5 MHz. 
31
P chemical shifts were 
referenced with respect to an external standard, 85% H3PO4, using the convention that low-
field, paramagnetic, deshielded values are positive (IUPAC d-scale). For all compounds 15-20 
mg of sample was dissolved in D2O (500 L). The concentrations thus varied in the 10-30 
mM range.  
Magnetic measurements. Magnetic susceptibility measurements were carried out on 
polycrystalline samples using a Quantum Design MPMS SQUID magnetometer operating in 
the 300-2 K temperature range and 0-5.5 T. Susceptibility measurements were performed with 
an applied field of 1000 Oe. Pascal’s constants were utilized to estimate diamagnetic 
corrections, the value in each case being subtracted from the experimental susceptibility data 
to give the molar magnetic susceptibility (M). 
Cell-growth inhibition assays. The human tumor cell line NCI-H460 (non-small cell lung 
cancer) was obtained from the National Cancer Institute and maintained at 100% humidity 
and 5% CO2 at 37 °C. Cell growth inhibition assays were carried out as described previously 
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.
20
 A broth microdilution method was used to determine the growth inhibition IC50 values. 
Briefly, ~5 x 10
4
 cells suspended in 100 µL of DMEM supplemented with 10% fetal bovine 
serum (FBS), 4.5 g/L glucose and L-glutamine and preserved with 1% penicillin–
streptomycin were seeded in 96-well plates (Corning Inc., Corning, NY) and incubated at 37 
°C in a 5% CO2 atmosphere. The cells were incubated with 1000 µM, 333 µM, 111 µM, 37 
µM, 12 µM, 4.1 µM, 1.4 µM, 0.46 µM, 0.15 µM, and 0.051 µM of compounds and H2O as a 
control for 4 days.
20
 Then, an MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell proliferation assay (ATCC, Manassas, VA) was performed to obtain dose–
response curves. The IC50 values of the free BP, Mo6Zol2 and Mo4Zol2Mn(III), which had 
been measured in MCF-7 cells in our first studies
21,22
 were re-determined here using the same 
conditions as for the other compounds (Table 1). 
In Vivo Tumor Model. Mice experiments were carried out basically as described in Kubo et 
al.
35
 Xenografts of human SK-ES-1 cells were initiated by subcutaneous injections of 1.5 × 
10
7
 cells into the right flank of four 6-week old athymic nude mice (CLEA, Tokyo, Japan). 
The mice received daily local injections of bisphosphonates (5 μg, for 28 days), or 
physiological saline. The smallest and largest diameters of the tumors, were measured weekly. 
Tumor volumes were calculated using the following formula: volume (mm
3
) =(smallest 
diameter)
2
 x (largest diameter)/2. All animal experiments were conducted according to the 
guidelines of the Institutional Animal Care and Use Committee, and the protocol was 
approved by the Ethics Committee for Experimental Animals of Hiroshima University. 
Statistical significance was determined by one-way ANOVA and independent t-test, using 
SPSSl (version 22, IBM); p < 0.05 was considered to be significant.  
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Supporting Information. Synthesis of ZolC6 and ZolC8, IR and NMR spectra, T= f(T) 
curve for Mo4Zol2Mn(II), representation of the A and B conformers of the Mo6L2 compounds, 
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Mo6(ZolC6)2. This material is available free of charge via the Internet at http://pubs.acs.org.  
 
Accession Codes 
CCDC 1547689 contains the supplementary crystallographic data for this paper. These data 
can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing 
data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data 
Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033. 
 
AUTHOR INFORMATION 
Corresponding Authors. eo@chad.scs.uiuc.edu; anne.dolbecq@uvsq.fr 
ACKNOWLEDGMENT 
This work was supported by Centre National de la Recherche Scientifique, Université de 
Versailles-Saint-Quentin-en-Yvelines, L'Agence Nationale de la Recherche (grant ANR-11-
BS07-011-01-BIOOPOM), and by the United States Public Health Service (National 
Institutes of Health grants GM065307 and CA158191). Flavien Bourdreux and Tarik Benali 
are gratefully acknowledged for the NMR measurements and the synthesis of lipophilic 
bisphosphonates respectively. 
 
REFERENCES
                                                 
1
 Special issue on polyoxometalates, Chem. Rev. 1998, 98, 1-390. 
 20 
                                                                                                                                                        
2
 Dolbecq, A.; Dumas, E.; Mayer, C. R.; Mialane, P. Hybrid Organic-Inorganic 
Polyoxometalate Compounds: From Structural Diversity to Applications. Chem. Rev. 2010, 
110, 6009. 
3
 Walsh, J. J.; Bond, A. M.; Forster, R. J.; Keyes, T. E. Hybrid Polyoxometalate Materials for 
Photo(electro-)chemical Applications. Coord. Chem. Rev. 2016, 306, 217. 
4
 Wang, S.-S.; Yang, G.-Y. Recent Advances in Polyoxometalate-Catalyzed Reactions. Chem. 
Rev. 2015, 115, 4893. 
5
 Lv, H.; Geletii, Y. V.; Zhao, C.; Vickers, J. W.; Zhu, G.; Luo, Z.; Song, J.; Lian, T.; 
Musaev, D. G.; Hill, C. L. Polyoxometalate Water Oxidation Catalysts and the Production of 
Green Fuel. Chem. Soc. Rev. 2012, 41, 7572. 
6
 Zheng, S.-T.; Yang, G.-Y. Recent Advances in Paramagnetic-TM-Substituted 
Polyoxometalates (TM = Mn, Fe, Co, Ni, Cu). Chem. Soc. Rev. 2012, 41, 7623. 
7
 Clemente-Juan, J. M.; Coronado, E.; Gaita-Ariño, A. Magnetic Polyoxometalates: From 
Molecular Magnetism to Molecular Spintronics and Quantum Computing. Chem. Soc. Rev. 
2012, 41, 7464. 
8
 Yang, P.; Lin, Z.; Bassil, B. S.; Alfaro-Espinoza, G.; Ullrich, M. S.; Li, M.-X.; Silvestru, C.; 
Kortz, U. Tetra-Antimony(III)-Bridged 18-Tungsto-2-Arsenates(V), [(LSb
III
)4(A--
As
V
W9O34)2]
10-
 (L = Ph, OH): Tuning Bioactivity On and Off by Ligand Substitution. Inorg. 
Chem. 2016, 55, 3718. 
9
 (a) Yamase, T. Anti-tumor, -viral, and -bacterial Activities of Polyoxometalates for 
Realizing and Inorganic drug. J. Mater. Chem. 2005, 15, 4773. (b) Hasenknopf, B. 
Polyoxometalates: Introduction to a Class of Inorganic Compounds and their Biomedical 
Applications. Front. Biosci. 2005, 10, 275. 
 21 
                                                                                                                                                        
10
 (a) Yamase, T.; Fujita, H. ; Fukushima, K. Medical chemistry of polyoxometalates. Part1. 
Potent Antitumor Activity of Polyoxomolybdates on Animal Transplantable Tumors and 
Human Cancer Xenograft. Inorg. Chim. Acta 1988, 151, 15. (b) Ogata, A.; Mitsui, S.; 
Yanagie, H.; Kasano, H.; Hisa, T.; Yamase, T.; Eriguchi, M. A Novel Anti-tumor Agent, 
Polyoxomolybdate Induces Apoptotic Cell Death in AsPC-1 Human Pancreatic Cancer Cells. 
Biomed. Pharmacother. 2005, 59, 240. 
11
 Wang, X. H.; Dai, H. C.; Liu, J. F. Synthesis and Characterization of Organotin-Substituted 
Heteropolytungstosilicates and their Biological Activity. Polyhedron 1999, 18, 2293. 
12
 Wang, X.; Liu, J.; Li, J.; Yang, Y.; Liu, J. ; Li, B.; Pope, M. T. Synthesis and Antitumor 
Activity of Cyclopentadienyltitatinium Substituted Polyoxotungstate [CoW11O39(CpTi)]
7-
 (Cp 
= eta
5
-C5H5). J. Inorg. Biochem. 2003, 94, 279. 
13
 Zhang, Z.-M.; Duan, X.; Yao, S.; Wang, Z.; Lin, Z.; Li, Y.-G.; Long, L.-S.; Wang, E.-B.; 
Lin, W. Cation-Mediated Optical Resolution and Anticancer Activity of Chiral 
Polyoxometalates Built from Entirely Achiral Building Blocks. Chem. Sci. 2016, 7, 4220. 
14
 Prudent, R.; Moucadel, V.; Laudet, B.; Barette, C.; Lafanechère, L.; Hasenknopf, B.; Li, J.; 
Bareyt, S.; Lacôte, E.; Thorimbert, S.; Malacria, M.; Gouzerh, P.; Cochet, C. Identification of 
Polyoxometalates as Nanomolar Noncompetitive Inhibitors of Protein Kinase CK2. Chem. 
Biol. 2008, 15, 683. 
15
 She, S.; Bian, S.; Hao, J.; Zhang, J.; Zhang, J.; Wei, Y. Aliphatic Organoimido Derivatives 
of Polyoxometalates Containing a Bioactive Ligand. Chem. Eur. J. 2014, 20, 16987. 
16
 Yang, H.-K. ; Cheng, Y.-X.; Su, M.-M.; Xiao, Y.; Hu, M.-B.; Wang, W.; Wang, Q. 
Polyoxometalate-Biomolecule Conjugates : a New Approach to Create Hybrid Drugs for 
Cancer Therapeutics. Bio. Org. Med. Chem. Let. 2013, 23, 1462. 
 22 
                                                                                                                                                        
17
 She, S.; Bian, S.; Huo, R.; Chen, K.; Huang, Z.; Zhang, J.; Hao, J.; Wei, Y. Degradable 
Organically-Derivatized Polyoxometalate with Enhanced Activity Against Glioblastoma Cell 
Line. Sci. Rep. 2016, 6, 33529. 
18
 (a) Singh, A. P.; Zhang, Y.; No, J.-H.; Docampo, R.; Nussenzweig, V.; Oldfield, E. 
Lipophilic Bisphosphonates Are Potent Inhibitors of Plasmodium Liver-Stage Growth. 
Antimicrob. Agents & Chemoth. 2010, 54, 2987. (b) Mukherjee, S.; Huang, C.; Guerra, K.; 
Wang, K.; Oldfield, E. Thermodynamics of Bisphosphonates Binding to Human Bone: a 
Two-Site Model. J. Am. Chem. Soc. 2009, 131, 8375. (c) Zhang, Y.; Cao, R.; Yin, F.; Lin, 
F.Y.; Wang, H.; Krysiak, K.; Mukkamala, D. Houlihan, K.; Li, J.; Morita, C.T.; Oldfield, E. 
Lipophilic Pyridinium Bisphosphonates: Potent Gamma Delta T Cell Stimulators. Angew. 
Chem. Int. Ed. 2010, 49, 1136. (d) Song, Y.; Lin, F.Y.; Yin, F.; Hensler, M.; Rodrigues 
Poveda, C.A.; Mukkamala, D.; Cao, R.; Wang, H.; Morita, C.T.; Gonzalez Pacanowska, D.; 
Nizet, V.; Oldfield, E. Phosphonosulfonates are Potent, Selective Inhibitors of 
Dehydrosqualene Synthase and Staphyloxanthin Biosynthesis in Staphylococcus Aureus. J. 
Med. Chem. 2009, 52, 976. (e) Zhang, Y.; Hudock, M. P.; Krysiak, K.; Cao, R.; Bergan, K.; 
Yin, F.; Leon, A.; Oldfield, E. Activity of Sulfonium Bisphosphonates on Tumor Cell Lines. 
J. Med. Chem. 2007, 50, 6067. (f) Clézardin, P. Bisphosphonates’ Antitumor Activity : an 
Unravelled Side of a Multifaceted Drug Class. Bone 2011, 48, 71. 
19
 (a) Banerjee, A.; Bassil, B. S.; Röschenthaler, G.-V.; Kortz, U. Diphosphates and 
Diphosphonates in Polyoxometalate Chemistry. Chem. Soc. Rev. 2012, 41, 7590. (b) Dolbecq, 
A.; Mialane, P.; Sécheresse, F.; Keita, B.; Nadjo, L. Functionalized Polyoxometalates with 
Covalently Linked Bisphosphonate, N-donor or Carboxylate Ligands: from Electrocatalytic to 
Optical Properties. Chem. Commun. 2012, 48, 8299. 
 23 
                                                                                                                                                        
20
 Compain, J.-D.; Mialane, P.; Marrot, J.; Sécheresse, F.; Zhu, W.; Oldfield, E.; Dolbecq, A. 
Tetra- to Dodecanuclear Oxomolybdate Complexes with Functionalized Bisphosphonate 
Ligands : Activity in Killing Tumor Cells. Chem. Eur. J. 2010, 16, 13741. 
21
 El Moll, H.; Zhu, W.; Oldfield, E.; Rodriguez-Albelo, L. M.; Mialane, P.; Marrot, J.; Vila, 
N.; Mbomekallé, I.-M.; Rivière, E.; Duboc, C.; Dolbecq, A. Polyoxometalates Functionalized 
by Bisphosphonate Ligands : Synthesis, Structural, Magnetic, and Spectroscopic 
Characterizations and Activity on Cell Lines. Inorg. Chem. 2012, 51, 7921. 
22
 Saad, A.; Zhu, W.; Rousseau, G.; Mialane, P.; Marrot, J. ; Haouas, M. ; Taulelle, F. ; 
Desspat, R.; Serier-Brault, H.; Rivière, E.; Kubo, T.; Oldfield, E.; Dolbecq, A. 
Polyoxometalate Bisphosphonate Heterometallic Complexes : Synthesis, Structure and 
Activity on a Breast Cancer Cell Line. Chem. Eur. J. 2015, 21, 10537. 
23
 Zhang, Y.; Cao, R.; Yin, F.; Hudock, M.P.; Guo, R.T.; Krysiak, K.; Mukherjee, S.; Gao, 
Y.G.; Robinson, H.; Song, Y.; No, J.H. Bergan, K.; Leon, A.; Cass, L.; Goddard, A.; Chang, 
T.K.; Lin, F.Y.; Beek, E.V.; Papapoulos, S.; Wang, A.H.;  Kubo, T.; Ochi, M.; Mukkamala, 
D.; Oldfield, E. Lipophilic Bisphosphonates as Dual Farnesyl/Geranygeranyl Diphosphate 
Synthase Inhibitors : an X-ray and NMR Investigation. J. Am. Chem. Soc. 2009, 131, 5153. 
24
 Xia, Y.; Liu, Y.-L.; Xie, Y.; Zhu, W.; Guerra, F.; Shen, S.; Yeddula, N.; Fischer, W.; Low, 
W.; Zhou, X.; Zhang, Y.; Oldfield, E.; Verma, I. M. A Combination Therapy for KRAS-
Driven Lung Adenocarcinomas Using Lipophilic Bisphosphonates and Rapamycin. Sci. 
Transl. Med. 2014, 6, 263ra161. 
25
 Thiel, J.; Ritchie, C.; Streb, C.; Long, D.-L.; Cronin, L. Heteroatom-Controlled Kinetics of 
Switchable Polyoxometalate Frameworks. J. Am. Chem. Soc. 2009, 131, 4180.  
26
 Taylor, R.; Kennard, O. Crystallographic Evidence for the Existence of C-H···O, C-H···N, 
and C-H···C1 Hydrogen-Bonds. J. Am. Chem. Soc. 1982, 104, 5063. 
 24 
                                                                                                                                                        
27
 See for example (a) Sun, T.; Cui, W.; Yan, M.; Qin, G.; Guo, W.; Gu, H.; Liu, S.; Wu, Q. 
Target Delivery of a Novel Antitumor Organoplatinum(IV)-Substituted Polyoxometalate 
Complex for Safer and More Effective Colorectal Cancer Therapy In Vivo. Adv. Mater. 2016, 
28, 7397. (b) Dong, Z.; Tan, R.; Cao, J.; Yang, Y.; Kong, C.; Du, J.; Zhu, S. ; Zhang, Y. ; Lu, 
J. ; Huang, B. ; Liu, S. Discovery of Polyoxometalate-based HDAC Inhibitors with Profound 
Anticancer In Vitro and In Vivo. Eur. J. Med. Chem. 2011, 46, 2477. (c) Wang, X.; Li, F.; Liu, 
S.; Pope, M. T. New Liposome-encapsulated-polyoxometalates: Synthesis and Antitumoral 
Activity. J. Inorg. Biochem. 2005, 99, 452. 
28
 (a) Yuen, T.; Stachnik, A.; Iqbal, J.; Sgobba, M.; Gupta, Y.; Lu, P.; Colaianni, G.; Ji, Y.; 
Zhu, L.-L.; Kim, S.-M.; Li, J.; Liu, P.; Izadmehr, S.; Sangodkar, J.; Bailey, J.; Latif, Y.; 
Mujtaba, S.; Epstein, S.; Davies, T. F.; Bian, Z.; Zallone, A.; Aggarwal, A. K.; Haider, S.; 
New, M. I.; Sun, L.; Narla G.; Zaidi, M. Bisphosphonates Inactive Human EGFRs to Exert 
Antitumor Actions. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 17989. (b) Stachnik, A.; Yuen, 
T.; Iqbal, J.; Sgobba, M.; Gupta, Y.; Lu, P.; Colaianni, G.; Ji, Y.; Zhu, L.-L., Kim, S.-M.; Li, 
J.; Liu, P.; Izadmehr, S.; Sangodkar, J.; Scherer, T.; Mujtaba, S.; Galsky, M.; Gomez, J.; 
Epstein, S.; Buettner, C.; Bian, Z.; Zallone, A.; Aggarwal, A. K.; Haider, S.; New, M. I.; Sun, 
L.; Narla, G.; Zaidi, M. Repurposing of Biphosphonates for the Prevention and Therapy of 
Nonsmall Cell Lung and Breast Cancer. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 17995. 
29
 Nada, M. H.; Wang, H.; Workalemahu, G.; Tanaka, Y.; Morita, C. T. Enhancing Adoptive 
Cancer Immunotherapy with Vγ2Vδ2 T Cells through Pulse Zoledronate Stimulation. J. 
Inmmunother. Cancer. 2017, 5, doi: 10.1186/s40425-017-0209-6. 
30
 Coscia, M.; Quaglino, E.; Iezzi, M.; Curcio, C.; Pantaleoni, F.; Riganti, C.; Holen, I.; 
Mönkkönen, H.; Boccadoro, M.; Forni, G.; Musiani, P.; Bosia, A.; Cavallo, F.; Massaia, M. 
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary 
 25 
                                                                                                                                                        
carcinogenesis by targeting the mevalonate pathway. J. Cell. Mol. Med. 2010, 14, 2803. 
31
 Martin, M. B.; Grimley, J. S.; Lewis, J. C.; Heath, III, H. T.; Bailey, B. N.; Kendrick, H.; 
Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N. J.; Docampo, R.; Croft, S. L.; 
Oldfield, E. Bisphosphonates Inhibit the Growth of Trypanosoma Brucei, Trypanosoma 
Cruzi, Leishmania Donovani, Toxoplasma Gondii, and Plasmodium Falciparum : a Potential 
Route to Chemotherapy. J. Med. Chem. 2001, 44, 909. 
32
 Sheldrick, G. M. SADABS, program for scaling and correction of area detector data, 
University of Göttingen, Germany, 1997. 
33
 Blessing, R. An Empirical Correction for Absorption Anisotropy. Acta Crystallogr. 1995, 
A51, 33. 
34
 Sheldrick, G. M. SHELX-TL version 5.03, Software Package for the Crystal Structure 
Determination, Siemens Analytical X-ray Instrument Division : Madison, WI USA, 1994. 
35
 Kubo, T.; Shimose, S.; Matsuo, T.; Tanaka, K.; Yasunaga, Y.; Sakai, A.; Ochi, M. 
Inhibitory Effects of a New Bisphosphonate, Minodronate, on Proliferation and Invasion of a 
Variety of Malignant Bone Tumor Cells. J. Orthop. Res. 2006, 24, 1138. 
 
 26 
 
 
 
 
